Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, asparaginase (Spectrila®) cannot be endorsed for use within NHS Wales as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia in paediatric patients from birth to 18 years and adult patients. |
||
|
||
Medicine details |
||
| Medicine name | recombinant L-asparaginase (Spectrila®) | |
| Formulation | 10 000 U powder for concentrate for solution for infusion | |
| Reference number | 2968 | |
| Indication | For use as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia in paediatric patients from birth to 18 years and adult patients. |
|
| Company | medac GmbH | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 29/04/2016 | |
| Date of issue | 03/05/2016 | |